Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

People should be concerned about flu every year

As temperatures begin to cool, coughing and sneezing inevitably follow. So begins flu season in the United States — and preventable deaths, says David Kimberlin, M.D., University of Alabama at Birmingham professor of pediatrics and president-elect of the Pediatric Infectious Diseases Society.

21 Sep 2011

Autopsy study reveals earliest 1918 pandemic influenza cases

Examination of lung tissue and other autopsy material from 68 American soldiers who died of respiratory infections in 1918 has revealed that the influenza virus that eventually killed 50 million people worldwide was circulating in the United States at least four months before the 1918 influenza reached pandemic levels that fall.

20 Sep 2011

Prevention is global health community's greatest challenge in fight against chronic diseases

"A new pandemic has emerged and is beginning to overshadow all others," "The chronic-disease pandemic will be the 'face' of global health in the coming decades ... an insidious pandemic for those who are affected, causing slow and subtle declines in health over years."

17 Sep 2011

Congressional cuts to global health R&D spending would hinder preparations for new pandemic threats

The movie "'Contagion' is fiction, but truth closely trails behind. It tells an effective story of why we need new vaccines, tests, drugs, and other tools to prevent, diagnose, and treat diseases to address existing and emerging global health threats," Kaitlin Christenson, coalition director of the Global Health Technologies Coalition (GHTC), writes in an opinion piece in The Hill's "Congress Blog."

17 Sep 2011

BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine

Vaxin Inc., a clinical stage vaccine development company, today announced that it has been awarded a contract valued at up to $21.7 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) for pre-clinical assessment, final manufacturing process development and the supply of clinical materials to support an IND filing and first-in-man dose ranging study of the company's proprietary anthrax vaccine, AdVAV.

17 Sep 2011

HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

The advanced development of a novel next-generation anthrax vaccine and a new type of anthrax antitoxin have received support through new contracts funded the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

16 Sep 2011

Viewpoints: NY Times on uninsured; Wilensky's 'sobering reflection'; caring for aging parents

Nearly one million more Americans went without health insurance in 2010 than in 2009. ... The only consolation was that government insurance programs were able to mitigate some of the damage. ... The new health care reforms will expand Medicaid coverage for the poor and provide subsidies to help middle-income people buy private health insurance.

16 Sep 2011

Something like 'Contagion' could happen for influenza

In the new movie "Contagion," fictional health experts scramble to get ahead of a flu-like pandemic as a drug-resistant virus quickly spreads, killing millions of people within days after they contract the illness.

15 Sep 2011

WHO warns drug-resistant TB spreading in Europe at 'alarming' rate, releases plan to fight disease

Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) "are spreading at an alarming rate in Europe and will kill thousands unless health authorities halt the pandemic, the World Health Organization (WHO) said on Wednesday" during the launch of "a new regional plan to find, diagnose and treat cases of the airborne infectious disease more effectively," Reuters reports.

15 Sep 2011

'Achilles' heels' within HCV virus

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two 'Achilles' heels' within the virus.

14 Sep 2011

“Contagion” movie entirely plausible

Hollywood's latest thriller “Contagion” seems to have captured the public’s interest with strong sales at the box office. In the movie tens of millions of people are wiped out by the rapid spread of a killer airborne disease. It's a scenario real-life experts say is entirely plausible.

14 Sep 2011

Breakthrough opens new avenues for hep C vaccine

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two ‘Achilles’ heels’ within the virus.

12 Sep 2011

Genetically modified ‘glow cat’ for HIV/AIDS research

U.S. researcher Eric Poeschla has produced three glowing genetically modified cats by using a virus to carry a gene, called green fluorescent protein (GFP), into the eggs from which the animals eventually grew. This method of genetic modification is simpler and more efficient than traditional cloning techniques, and results in fewer animals being needed in the process.

12 Sep 2011

Non-communicable disease epidemic a global problem

Later this month the United Nations will convene a high-level meeting on non-communicable diseases. The world's global health news has been so dominated by infectious culprits - HIV/AIDS, malaria, tuberculosis, influenza - that it's easy to forget just how big a toll conditions like diabetes, cancer and heart and lung disease take say experts.

9 Sep 2011

Nexera to submit amended claims for FDA 510(k) clearance of SpectraShield 9500 Surgical N95 Respirator

Nexera Medical, Inc., today announced plans to submit to the U.S. Food and Drug Administration amended antimicrobial claims for its current 510(k) clearance for the SpectraShield 9500 Surgical N95 Respirator with embedded antimicrobial technology. The expanded antimicrobial claims will be supported by test data on the inactivation performance of certain strains of viruses.

8 Sep 2011

Apply lessons from the AIDS response to NCD control and prevention in developing countries

In anticipation of the September 2011 U.N. High-level Meeting on Non-Communicable Diseases (NCDs), low- and middle-income countries "should not only look at the lessons learned in the control of NCDs in developed countries, but also those from other areas of public health, especially AIDS, which can inform the design of an effective and sustainable response to NCDs in developing countries," Rebecca Dirks from FHI 360 and colleagues write in this PLoS Medicine Policy Forum editorial piece.

8 Sep 2011

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.

7 Sep 2011

Zimbabwe President Robert Mugabe urges men to take larger role in HIV prevention

"Zimbabwe President Robert Mugabe on Monday opened a national HIV and AIDS conference with a call for the nation's men to take a larger role in the response to the deadly pandemic, not only for their own health but that of women and children," VOA News reports.

7 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

NanoViricides, Inc. announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide anti-influenza therapeutics program.

6 Sep 2011

Pandemic News and Research

Further Reading

People should be concerned about flu every year

Autopsy study reveals earliest 1918 pandemic influenza cases

Prevention is global health community's greatest challenge in fight against chronic diseases

Congressional cuts to global health R&D spending would hinder preparations for new pandemic threats

BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine

HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

Viewpoints: NY Times on uninsured; Wilensky's 'sobering reflection'; caring for aging parents

Something like 'Contagion' could happen for influenza

WHO warns drug-resistant TB spreading in Europe at 'alarming' rate, releases plan to fight disease

'Achilles' heels' within HCV virus

“Contagion” movie entirely plausible

Breakthrough opens new avenues for hep C vaccine

Genetically modified ‘glow cat’ for HIV/AIDS research

Non-communicable disease epidemic a global problem

Nexera to submit amended claims for FDA 510(k) clearance of SpectraShield 9500 Surgical N95 Respirator

Apply lessons from the AIDS response to NCD control and prevention in developing countries

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

Zimbabwe President Robert Mugabe urges men to take larger role in HIV prevention

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

Best practices - optimize qPCR processes for pathogen detection eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News